2024/09/26 17:36:24 | |
---|---|
Price | |
0.05 CHF | |
Difference | 25.00% (0.01) |
ISIN | CH0106213793 |
Symbol | POLN |
Exchange | SIX Swiss Exchange |
Currency | CHF |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 4 EUR |
Benchmark | SWISS MARKET INDEX |
Bid (Bid size) | 0.05 CHF (30,000) |
Ask (Ask size) | 0.04 CHF (21,982) |
Open | 0.05 CHF |
High | 0.05 CHF |
Low | 0.05 CHF |
Close (prev. day) | 0.04 CHF |
VWAP | 0.050787 CHF |
Volume (pcs) | - |
Trading volume | - |
Number of trades | 1 |
Last size | - |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/09/11 | Global Equity Ratings | ||
2024/09/05 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/24 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings |
2024/09/26 17:36:24 | |
---|---|
Price | |
0.05 CHF | |
Difference | 25.00% (0.01) |
ISIN | CH0106213793 |
Symbol | POLN |
Exchange | SIX Swiss Exchange |
Currency | CHF |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 4 EUR |
Benchmark | SWISS MARKET INDEX |
Bid (Bid size) | 0.05 CHF (30,000) |
Ask (Ask size) | 0.04 CHF (21,982) |
Open | 0.05 CHF |
High | 0.05 CHF |
Low | 0.05 CHF |
Close (prev. day) | 0.04 CHF |
VWAP | 0.050787 CHF |
Volume (pcs) | - |
Trading volume | - |
Number of trades | 1 |
Last size | - |
6m | 1Y | 3Y | |
Perf (%) | -35.06% | -83.92% | -97.45% |
Perf (abs.) | -0.03 | -0.26 | -1.91 |
Beta | -1.19 | -1.29 | 0.19 |
Volatility | 272.71 | 294.48 | 184.20 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.05 CHF (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.05 CHF (0) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.06 CHF (185,712) |
Ø price 250 days | Ø volume 250 days (pcs.) | 0.10 CHF (181,964) |
YTD High | date | 1.06 CHF (2024/01/22) |
YTD Low | date | 0.03 CHF (2024/06/12) |
52 Weeks High | date | 1.06 CHF (2024/01/22) |
52 Weeks Low | date | 0.01 CHF (2023/11/14) |
SPEXIS LTD. |
- - |
Hegenheimermattweg 125 - 4123 Allschwil |
Telefon: +41-61-567-16-00 |
Fax: +41-61-567-16-01 |
E-mail: info@spexisbio.com |
Spexis Ltd. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of respiratory therapeutics. The firm focuses on rare, chronic respiratory diseases (CRD) and chronic lung infections in cystic fibrosis. Its product pipeline includes ColiFin, Inhaled Murepavadin, Balixafortide (POL6326), OMPTA, EBX-002, and POL6014 (Lonodelestat). The company was founded by Daniel Obrecht and Jean-Pierre Obrecht in 1996 and is headquartered in Allschwil, Switzerland. |
Jeffrey D. Wager | Chairman of Managing Board |
Jürgen Fröhlich | Member of Executive Committee |
Dan Hartman | Member of the administrative board |
Dennis Ausiello | Member of the administrative board |
Kuno Sommer | Member of the administrative board |
Robert Clarke | Member of the administrative board |
Bernard Bollag | Member of the administrative board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer